Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Procyon Biopharma Inc. -- Ignore unavailable to you. Want to Upgrade?

To: thebeach who wrote (231)	2/10/2000 12:41:00 PM
From: thebeach	Read Replies (1) \| Respond to of 356

FOR: PROCYON BIOPHARMA INC. CDNX SYMBOL: PBP FEBRUARY 10, 2000 Procyon Biopharma Announces Additional Investment From Innovatech du Grand Montreal MONTREAL, QUEBEC--Procyon BioPharma Inc. ("Procyon") announced today that Innovatech du Grand Montreal has purchased an additional $400,000 in Procyon common shares bringing Innovatech's total investment in the Company to $600,000. Since last November, Procyon has succeeded in raising approximately $3.5 million. This includes $500,000 recently realized through the exercise of options by Yorkton Securities, employees, directors and other shareholders and a $3 million private placement from Innovatech and T2C2, another key Quebec-based venture capital firm, as well as from European and other investors. "Procyon has interesting near-term product candidates and two anti-cancer platform technologies which we believe have potential," said Hubert Manseau, President of Innovatech du Grand Montreal. "We are finding that knowledgeable members of the investment community are understanding the potential of Procyon's technologies and pipeline more and more and are ready to support us in our development activities," stated Hans J. Mader, Procyon's President and CEO. "We appreciate their confidence and support." Procyon BioPharma Inc. is a publicly listed, biopharmaceutical company focused principally on advancing two powerful platform technologies that have the potential to diagnose and treat cancer. Procyon's Antinuclear Autoantibodies (ANAs) bind specifically to multiple cancer cell types strongly enhancing the immune response to cancer cells. Prostate Secretory Protein (PSP94) is a naturally occurring human protein that has the potential to treat prostate cancer by inhibiting abnormal prostate cell growth. In addition, the estimation of PSP94 levels in prostate cancer patients may have prognostic and diagnostic applications. Procyon also has two late-stage products: FIBROSTAT(TM), a topical cream for the management of newly formed scars following surgery or burns and COLOPATH(TM), a rapid, non-invasive screening test for colorectal cancer. Procyon's shares trade on the CDNX under the ticker symbol, PBP. The CDNX has neither approved nor disapproved the information contained in this release. -30-